Abridge's latest publicly disclosed primary financing record is a $300M Series E dated June 24, 2025. The event is shown on the company page using the event date—not the date Captables published this historical profile.
Andreessen Horowitz, A16z Scout Fund are identified as lead investors. Other named participants include Khosla Ventures, CVS Health, IVP, Lightspeed Venture Partners, Pillar VC, Spark Capital, Union Square Ventures, Elad GIL, Esther Dyson, Yoshua Bengio.
The preceding primary records in the ledger are $250M Series D dated February 17, 2025; $150M Series C dated February 23, 2024; $30M Series B dated October 26, 2023. These entries describe disclosed company financings; they do not include every secondary trade, employee tender, valuation mark or rumored transaction unless those events are separately labeled in the company ledger.
Abridge is ranked number 63 in the Captables Private 100 source universe. It operates in Healthcare AI and is based in United States. Its $5.30B ranking value is a third-party snapshot and should not be treated as a current executable share price or as the valuation for this round.
The round is currently supported by a public financing-database entry rather than an issuer filing, so Captables labels it as database-listed evidence. This page is a public-source reconstruction, not the issuer's stock ledger or legal capitalization table; undisclosed terms remain undisclosed and readers can submit stronger evidence for editorial review.